Diabetic neuropathies …

Peripheral Neuropathies

Updated 01.04.2025
Released 03.08.1996
Expires For CME 01.04.2028

Diabetic neuropathies

Authors: Mamatha Pasnoor MD FAAN, Mazen M Dimachkie MD

See Contributor Disclosures

Editor: Louis H Weimer MD

Cite this article

Diabetic neuropathies

In This Article

Quick Link

Introduction

Overview

Diabetic neuropathies include a variety of disorders that afflict diabetics fairly exclusively and are characterized by variable degrees of peripheral nerve damage. Earlier pathophysiology mainly focused on hyperglycemia causing nerve damage; however, evidence suggests contributions from obesity and dyslipidemia in addition to hyperglycemia. Clinical syndromes include symmetric and asymmetric forms. Unfortunately, there has been no progress in reversing or arresting the condition. In addition to several anticonvulsant and antidepressant medications, evidence has shown that combinations of these medications, topical drugs, and implanted electrical spinal cord stimulation may be effective in patients with refractory pain.

Key points

	• Diabetes is the leading cause of peripheral polyneuropathy, and diabetic neuropathy is the most prevalent complication of diabetes, affecting about half of diabetic patients.
	• Other common causes of neuropathy should be excluded.
	• The diagnosis of diabetic polyneuropathy includes a variety of modalities that test more specifically various peripheral nerve fibers including large fiber, small fiber somatic, and small fiber autonomic fibers.
	• Although chronic distal symmetric sensorimotor polyneuropathy is the most common type of diabetic neuropathy, other symmetric and asymmetric acute and chronic diabetic neuropathies are not uncommonly encountered in neurologic clinical practice.
	• Optimal glucose control, along with weight management and managing hyperlipidemia, remain as important prevention and treatment strategies in diabetic polyneuropathy.
	• Various pharmacologic and nonpharmacologic treatments are available for the management of neuropathic pain; however, comorbidities and potential drug-drug interactions should be considered in offering judicious treatment choices.

Historical note and terminology

Diabetes mellitus has four major systemic complications: (1) neuropathy, (2) retinopathy, (3) nephropathy, and (4) vasculopathy. Diabetic neuropathy is defined as the presence of symptoms and signs of peripheral nerve dysfunction in patients with diabetes. In addition, diabetes remains the leading cause of peripheral polyneuropathy in developed countries.

Diabetic neuropathies consist of a variety of syndromes resulting from different types of damage to peripheral or cranial nerves. These complications of diabetes have been recognized for at least two centuries. In the late 1800s, a series of papers appeared in which many of the subtypes of diabetic neuropathies were defined (05; 87; 14; 114). Included in these descriptions are patients with diabetic sensorimotor polyneuropathy as well as others with proximal diabetic, truncal, median, and ulnar neuropathies. Bruns focused further on the entity of proximal diabetic neuropathy (25). Diabetic polyneuropathy was recognized as having various manifestations; Leyden identified three subtypes: painful, ataxic, and paralytic. Autopsy studies on several patients showed peripheral nerve degeneration (87; 14). In 1922, Kraus proposed a classification of diabetic neuropathies into polyneuropathy and mononeuropathy as well as motor, sensory, and cranial types (81). The contemporary and clinical classification of diabetic neuropathies is shown in Table 1 (139; 18; 136; 106).

Table 1. Classification of Diabetic Neuropathies

Symmetric polyneuropathies
Relatively fixed deficits
	• Distal symmetric sensorimotor polyneuropathy • Autonomic neuropathy • Pseudosyringomyelic neuropathy • Pseudotabetic neuropathy • Small fiber neuropathy
Episodic or transient symptoms
	• Hyperglycemic neuropathy • Acute painful sensory neuropathy or diabetic neuropathic cachexia • Treatment-induced neuropathy
Asymmetric/focal and multifocal neuropathies
	• Cranial neuropathies • Truncal neuropathy • Proximal diabetic neuropathy (diabetic amyotrophy, diabetic radiculoplexopathy) • Focal limb mononeuropathies
Modified and adapted from (106).

Clinical manifestations

Presentation and course

An important fundamental clinical point is that even though distal symmetric sensorimotor polyneuropathy is the most frequent of the diabetic neuropathies, many patients have more than one of the conditions or types of neuropathy listed in Table 1, either sequentially or concomitantly. Both type 1 and type 2 diabetics are at risk for these neuropathies.

Distal symmetric sensorimotor polyneuropathy. This is the most common form of diabetic neuropathies. Many physicians inadequately assume that the term diabetic neuropathy is synonymous with distal symmetrical polyneuropathy because the latter constitutes about three fourths of all diabetic neuropathies. Symptoms are mainly sensory and insidious in onset. The prominent symptom is often reduced sensation, but there may also be paresthesias, tingling, burning, and neuropathic pain. Indeed, these "negative" and "positive" sensory symptoms may coexist. Symptoms begin distally in the toes and the feet and gradually extend proximally. Later, the fingers and hands may become affected, again with proximal spread. When extensive, the anterior abdominal wall is involved, and the sensory loss gradually spreads laterally around the trunk. Motor involvement is less frequent than sensory. However, when severe, this neuropathy causes weakness of distal leg muscles and later of the intrinsic hand muscles. Unsteady walking due to sensory ataxia is the result of large fiber sensory loss with or without concomitant weakness. Although this chronic neuropathy is related to the duration and severity of hyperglycemia, it can occasionally be the presenting symptom of occult diabetes mellitus, and significant sensorimotor and autonomic abnormalities may occur in patients with mild degrees of hyperglycemia. Patients with chronic and severe polyneuropathy have increased risk of foot ulceration, which contributes to lower extremity amputations in diabetic patients. This is due in part to a combination of lack of protective sensation, abnormal sweating, and poor wound healing.

Episodic or transient presentation. Three uncommon and unusual subacute sensory neuropathy syndromes are characterized by their eventual recovery:

(1) Treatment-induced neuropathy of diabetes, previously named insulin neuritis, is classically painful and affects small somatic sensory and autonomic fibers, and rarely affects large, myelinated nerve fibers. It has been reported in both type 1 and 2 diabetes mellitus after rapid glycemic control, more common in type 1 (59). This often parallels with a worsening retinopathy and resolves in weeks or months (30; 91; 60). Treatment-induced neuropathy may occasionally manifest as diabetic lumbosacral radiculoplexus neuropathy (128; 150). A reduction of HbA1c more than 4% over a 3-month period has an 80% absolute risk of developing this iatrogenic treatment-induced neuropathy (60).

(2) Acute painful sensory neuropathy with weight loss, also termed “diabetic neuropathic cachexia,” is usually seen in established type 1 diabetics, often male, who for unclear reasons experience rapid and severe weight loss (12). The weight loss is dramatic and is a key feature. Slow recovery occurs when body weight normalizes, which may take up to 1 to 2 years.

The clinical examination for polyneuropathy focuses on demonstrating impaired distal sensation distally, hypo- or areflexia, and weakness. Because the sensory fiber involvement may be restricted (see below), it is important to test for small fiber sensory loss using pinprick and temperature testing as well as for large fiber loss--touch, vibration, reflex loss, and weakness. The use of monofilaments to assess touch-pressure sensation has become popular (148).

Diabetic autonomic neuropathy. Autonomic nerve fibers are invariably involved in chronic sensorimotor polyneuropathy. This is frequently subclinical in the early stages of the polyneuropathy, although it may be detected using sensitive methods to measure and quantitate autonomic function. When symptomatic, this may result in impaired sweating and some cutaneous vasomotor changes. However, the autonomic nervous system may become widely involved and dominate the clinical picture. In most patients the symptoms are not severe, but some have devastating diabetic autonomic neuropathy (147). The neuropathy may affect all or selected organs or systems innervated by the autonomic nervous system. In autonomic neuropathies, cardiovascular, gastrointestinal, and urogenital systems may be affected and sudomotor function impaired. Thus, one or more of the following may develop: gastroparesis, diarrhea, constipation, orthostatic hypotension, bladder dysfunction, and erectile dysfunction. About 40% of diabetic men develop erectile dysfunction; this may occur in the absence of, or in association with, other manifestations of diabetic autonomic neuropathy.

The clinical examination of the autonomic nervous system is limited. Cardiovascular autonomic testing is most simply performed by evaluating the heart rate. A fixed heart rate on deep breathing has the greatest specificity for cardiac parasympathetic dysfunction (approximately 80%). A resting tachycardia, or when the patient goes from lying to standing, also indicates vagal parasympathetic dysfunction. The simple bedside measurement of lying-standing blood pressure change is an important test for sympathetic vasoconstrictor dysfunction. Dry feet indicate a failure of distal sweating. Reduced lacrimation can be detected using Schirmer strips.

Diabetics with cardiac autonomic neuropathy have significantly increased overall mortality (149). Hence, autonomic assessment may be used for cardiovascular risk stratification in diabetic patients, and as indicator for more aggressive pharmacologic therapies and lifestyle management of comorbid conditions.

Diabetic small fiber neuropathy. Damage to the small sensory nerve fibers is one of the earliest manifestations of diabetic neuropathy. This often starts with episodic pain in toes that slowly spreads to the feet and sometimes above ankles and fingers. The type of neuropathic pain associated with small fiber neuropathy is variable and often mixed, including burning, electrical shocks, tingling, pins and needles, painful cold, uncomfortable numbness, and frequent itching. On examination, there is often touch and pin hypoesthesia, tactile hyperesthesia or allodynia, or both. These two findings when combined have excellent sensitivity (83%) and specificity (90%) for the diagnosis of neuropathic pain and diabetic small fiber neuropathy (131). There is evidence suggesting parallel damage to small and large nerve fibers (161).

Cranial neuropathies. Cranial nerve palsies are rare acute complications of diabetes. The most common cranial neuropathy is third nerve palsy (63). This typically affects patients over the age of 50 years and is rare in children. Only one fourth of patients have an associated diabetic peripheral neuropathy (63). It is usually abrupt and associated with pain. Pupillary function is usually spared. Pupillary sparing has been attributed to ischemia occurring centrally within the third nerve, preserving the peripherally located parasympathetic pupilloconstrictor fibers. This contrasts with compressive lesions of the oculomotor nerve, such as aneurysm of the posterior communicating artery, in which the pupillary fibers usually are affected early. Sixth nerve palsies also occur in diabetics. It is unclear whether seventh nerve palsies occur more frequently in diabetics.

Truncal neuropathy. Truncal or thoracic neuropathy usually presents subacutely with painful paresthesias in variable size patches unilaterally or bilaterally in the trunk (132). This usually involves the T4 through T12 spinal nerve roots individually or over several contiguous nerves. Associated involvement of motor nerve fibers can lead to bulging of the abdominal wall in the paresthetic areas, often referred to as pseudohernia and best appreciated when the patient is standing. Clinical examination usually reveals a patch of sensory abnormality in the region of the symptoms. Abnormalities consist of varying degrees of sensory blunting that can be subtle or hyperalgesia or allodynia.

Focal limb neuropathies. Many studies have shown that peripheral nerve compressive lesions are more frequent in diabetics than in nondiabetics. They add to the disability already imposed by the polyneuropathy that is almost always present. Diabetes mellitus has been long considered a risk factor for carpal tunnel syndrome and is found in approximately 20% to 30% of individuals with diabetes, with the highest rates observed in those who have diabetic neuropathy and a longer duration of the disease. A metaanalysis of 42 observational studies identified diabetes as a risk factor for carpal tunnel syndrome, with an odds ratio of 1.68 (95% CI 1.45-1.94) (124). In contrast, the association of ulnar nerve entrapment (UNE) and diabetes is less clear (120). Large percentage of diabetic patients show electrodiagnostic abnormalities of ulnar nerve entrapment; however, only small percentage of patients are symptomatic (119; 66). The prevalence of peroneal neuropathy at the knee in individuals with diabetes varies widely, ranging from 3% to 60%, with the majority of cases being subclinical (29). The radial, tibial, and lateral femoral cutaneous nerves are also susceptible to entrapment in diabetes. Meralgia paresthetica (mononeuropathy of the lateral femoral cutaneous nerve) is associated with diabetes mellitus irrespective of obesity and advanced age (105). The incidence rate in the diabetic population is more than seven times the general population. Focal neuropathies can easily go undetected because the symptoms are attributed to polyneuropathy. When sensory or motor symptoms are more prominent in the hands than feet, carpal tunnel syndromes or ulnar neuropathies should be suspected and excluded.

Diabetic proximal (proximal diabetic neuropathy, diabetic radiculoplexus neuropathy, diabetic amyotrophy). This syndrome "goes by a bewildering variety of names" (40). These include diabetic amyotrophy, diabetic lumbosacral plexopathy, diabetic polyradiculopathy, proximal diabetic neuropathy, ischemic mononeuropathy multiplex associated with diabetes mellitus, Bruns-Garland syndrome, and diabetic lumbosacral radiculoplexus neuropathy (13; 43). It is also misleadingly referred to as “diabetic femoral neuropathy.”

This condition may develop in longstanding diabetics during periods of poor metabolic control and weight loss, but it can also occur in mild and well controlled diabetics or be the presenting feature of diabetes. Diabetic lumbosacral radiculoplexopathy may be treatment-induced, manifesting during aggressive treatment of diabetes (128; 150). The clinical features are variable, and the onset may be gradual or sudden. A prominent feature is pain that is often severe and located in the back, hips, and thighs; occasionally, pain is mild or even absent. The patient may have the systemic symptoms of anorexia, malaise, and weight loss. This is usually a monophasic condition; however, relapses may be seen in small percentage of patients (156; 144).

On examination, the usual motor features are unilateral wasting and weakness of the proximal legs and hip girdle, but distal muscles may also be affected. The quadriceps muscle group is often most affected. The weakness varies from mild to so severe as to render the patient wheelchair-bound. A diagnosis of femoral neuropathy is often made, but detailed clinical and electrophysiological tests will usually show more extensive involvement. These patients may be misdiagnosed as having lumbosacral radiculopathies, leading to unnecessary surgeries before the neurologist identifies the correct diagnosis. Proximal sensory involvement is variable and often minor compared with the motor abnormalities. All these symptoms and signs are usually, but not always, asymmetrical. Patients frequently have coexisting sensorimotor polyneuropathy.

A similar disorder without pain though sharing many of the other features of the painful syndrome (weight loss, proximal weakness, subacute onset) has been also described. This variant, however, tends to have more bilateral and symmetrical onset, is more slowly progressive, and often results in significant disability (34; 57).

Patients with a similar clinical entity sharing many of the clinical and pathological features of diabetic lumbosacral radiculoplexus neuropathy but affecting the upper extremity are rarely described. These patients have a disorder that mimics idiopathic neuralgic amyotrophy (brachial neuritis) with acute pain followed by weakness. The term “diabetic cervical radiculoplexus neuropathy” has been proposed (97).

Superimposed chronic inflammatory demyelinating polyneuropathy (CIDP). Although a study suggested otherwise (83), it is possible that a chronic inflammatory demyelinating polyneuropathy-like syndrome may occur more frequently in diabetics than in nondiabetics (73; 62; 37; 127). Features that distinguish chronic inflammatory demyelinating polyneuropathy from the far more frequent chronic diabetic sensorimotor polyneuropathy include rapidly progressive neuropathy, the presence of oligoclonal bands in cerebrospinal fluid, demyelinating features on nerve conduction studies, proximal nerve and brachial plexus enlargements on ultrasound (135), and a good response to a therapeutic trial of immunomodulatory treatments (intravenous immunoglobulin or corticosteroids). Unfortunately, high CSF protein also may be found in patients with diabetes without chronic inflammatory demyelinating polyneuropathy (80). Although proportion of treatment responders was comparable in patients with and without diabetes (70% vs. 74.9%, respectively), a study showed a class I evidence that IVIg does not reduce disability in patients with chronic inflammatory demyelinating polyneuropathy and diabetes (20; 116). Making a diagnosis of true chronic inflammatory demyelinating polyneuropathy in diabetic patients remains challenging because demyelinating features may be present on electrophysiology in patients with diabetes. Hence, these electrophysiologic findings should not be used as the sole criteria (absent clinical findings) for the diagnosis of an immune-mediated neuropathy such as CIDP.

Impaired glucose tolerance (prediabetes) and neuropathy. Increasingly, prediabetes has been regarded as a cause of painful peripheral neuropathy. Patients with mild, predominantly sensory neuropathy, but with normal fasting blood glucose, may have impaired glucose tolerance on oral glucose tolerance testing. The prevalence of neuropathy in patients with prediabetes may be higher than in nondiabetics, though this is still a subject for debate (26; 85). Given commodities in prediabetes, contributions from the metabolic syndrome as the cause of neuropathy should be also considered (76).

The diagnosis of impaired glucose tolerance (prediabetes) remains challenging and often is under dispute by both physicians and patients. The diagnostic sensitivity of hemoglobin A1c for prediabetes is unclear, although the specificity is very high. In at-risk patients with prediabetes and normal hemoglobin A1c, oral glucose tolerance test is recommended (26). The American Diabetes Association recommends that two tests (fasting glucose, HbA1c measurement, 2-hour plasma glucose level after an oral glucose tolerance test) obtained at two separate visits should be abnormal for confirmation of the diagnosis of diabetes (06). Elevated levels of fasting glucose and HbA1c from a single baseline blood sample was shown to have moderate sensitivity (55%) but high specificity to identify patients who will develop frank diabetes in the next 5 years of follow-up (98%), with specificity increasing to 99.6% at 15 years (126).

Prognosis and complications

Diabetic sensorimotor polyneuropathy usually worsens slowly over the years. About half of all diabetic neuropathies are asymptomatic and remain only mildly symptomatic in most patients (111). Others may be severely troubled by one or more of the following complications: severe neuropathic pain, numbness and other sensory symptoms in the feet and hands, distal limb weakness late in the course of disease, and even falls due to proprioceptive loss. Falls are frequent in older diabetic patients, particularly with lower extremity weakness or vibration loss (67). These patients should be counseled and undergo gait evaluation, walking aids, and physical therapy. Polyneuropathy is a risk factor for foot ulcers, Charcot joints, and amputation.

Acute painful sensory neuropathy usually improves after several weeks or months. Truncal neuropathy will also usually resolve, although this may take many months. Some patients have repeated episodes, essentially having chronic pain.

Diabetic autonomic neuropathy is generally considered to be a progressive disorder and has long been suspected as being a risk factor for renal failure, myocardial infarction, and sudden unexpected death (122; 152). Impaired cardiovascular autonomic function as measured by heart rate variability is associated (ie, relative risk is doubled) with an increased risk of silent myocardial ischemia and mortality (147). One study showed that sudden cardiac death in diabetics was correlated with atherosclerotic heart disease and nephropathy and to a lesser degree with diabetic autonomic neuropathy; the latter is unlikely to be the primary cause of cardiac death (94).

In proximal diabetic neuropathy, the weakness initially worsens over weeks or sometimes months, although the pain resolves earlier. However, this weakness eventually improves spontaneously to some extent after 3 to 18 months. Mild weakness, discomfort, and stiffness often persist for years, and only 40% of patients make a full recovery (38; 40). Relapses on the same or other side occasionally occur.

Both the third and sixth cranial neuropathies almost always recover completely or nearly so in a period of a few weeks to a few months. Whether the prognosis of seventh nerve palsy (Bell palsy) is different in diabetics compared to the general population remains unresolved.

Carpal tunnel syndrome in diabetics should be managed exactly as in nondiabetics, ie, wrist splints or decompression (02). Improvement, at least back to the baseline polyneuropathy symptoms, if present in the hands, is to be expected following decompression. No data exist regarding the results of surgical interventions for ulnar and other focal neuropathies in diabetics.

The prognosis for the rare case of diabetes associated with definite clinical evidence of chronic inflammatory demyelinating polyneuropathy (143) is generally good when it is treated with immunomodulatory therapy. It is hoped that the treatment of impaired glucose tolerance will improve or stabilize the neuropathy, but addressing causes of the metabolic syndrome are also important (76).

Clinical vignette

A 35-year-old man had type 1 diabetes since the age of 13 years. At the time of presentation, he had retinopathy for 5 years and nephropathy for 4 years. Sensorimotor polyneuropathy was recognized at the age of 30, and he developed a Charcot joint of the left ankle at the age of 34.

Autonomic dysfunction began at 25 years of age with erectile dysfunction, which was managed with an implant. He later developed intermittent diarrhea but was occasionally constipated. Bladder function remained normal. Orthostatic hypotension on standing up from bed was troublesome, so he sat before standing. Syncopal episodes were increasing. Sweating was also abnormal (from the neck down to the mid-thighs but dry everywhere else).

Examination showed moderate distal wasting and weakness in the limbs as well as complete areflexia. Light touch and pinprick sensations were diminished in the tips of the fingers as well as in the feet to the mid-calf. Vibration and proprioception sensations were absent in the toes. Blood pressure was 160/90 mm Hg lying and 100/60 mm Hg standing. His pulse was 90 per minute in both positions. When sitting in a warm examination room, his hands and feet were completely dry, but his trunk was excessively sweaty, and his shirt became completely wet.

Improved diabetes control was attempted, but the patient was not compliant. The erectile dysfunction was managed with an implant, diarrhea with diphenoxylate hydrochloride, and the orthostatic hypotension with fludrocortisone.

Comment. This young type 1 diabetic had moderate to severe sensorimotor polyneuropathy, leading to foot complications. Erectile dysfunction developed without, at first, other manifestations of diabetic autonomic neuropathy, but chronic diarrhea, orthostatic hypotension, fixed tachycardia (lack of vagal innervation to the heart), and sweating abnormalities developed later. Patients with these neurologic syndromes frequently have other diabetic complications such as retinopathy and nephropathy.

Biological basis

Etiology and pathogenesis

Pathogenesis. In spite of massive research efforts, the pathogenesis of diabetic neuropathies remains incompletely understood. Several different and sometimes overlapping mechanisms contribute to nerve damage. The different types of neuropathy probably have different pathogenic mechanisms.

In chronic sensorimotor polyneuropathy, chronic hyperglycemia, impaired insulin signaling, and a variety of its metabolic sequelae, hyperlipidemia, and microvascular-hypoxic factors are the major mechanisms (not mutually exclusive) thought to be responsible (28; 64; 16; 50; 145; 51).

It has been postulated that the immune system plays a role in the pathogenesis of certain diabetic neuropathies. This may be in the form of an immune-mediated attack on nerves or to their vasa nervora (as in the case of diabetics with chronic inflammatory demyelinating polyneuropathy, and proximal diabetic neuropathy respectively) (121; 92; 46). Some studies showed evidence of cytokine and chemokine production in diabetic neuropathy patients (112; 41; 90; 71). In diabetic autonomic neuropathy, this mechanism is supported by a number of observations. Lymphocytic infiltrates in sympathetic ganglia infer immune-mediated damage (42), although these findings have been questioned (125). Higher levels of TNF-α were found in type 1 diabetic patients with autonomic neuropathy compared with type 1 diabetic patients without autonomic neuropathy (112). Antiganglioside antibodies and other inflammatory markers were seen to be elevated in diabetic neuropathy patients compared to normal and diabetics without neuropathy (58).

Endoneurial microangiopathy likely plays a significant role in peripheral nerve dysfunction and pathology of diabetic polyneuropathy (53). The microvascular disease concept in diabetic sensorimotor polyneuropathy no longer addresses the complexities and unique qualities of direct neuronal involvement (164). However, the vasculitic abnormalities associated with proximal diabetic neuropathy may be the result of immune-mediated damage (121; 92; 118; 48). The response of some patients with proximal diabetic neuropathy to corticosteroids and intravenous immunoglobulin provides indirect support for an immune-mediated pathogenesis. In diabetics with chronic inflammatory demyelinating polyneuropathy, as in non-diabetics with this disorder, the mechanism is thought to be immunological, and the response to immune modulatory treatments supports this assertion (134).

The increased prevalence of focal limb neuropathies in diabetics is probably attributable to major nerve trunks being excessively prone to damage by external pressure. Animal experiments have shown that the presence of a polyneuropathy enhances the tendency to develop pressure palsies. Rats rendered diabetic with streptozotocin develop plantar neuropathies earlier and in a more severe fashion when they are kept in wire-mesh floor cages than rats that did not have diabetes (165). When a focal neuropathy occurs suddenly, the mechanism may be a nerve infarct.

Risk factors. Known risk factors for the development of polyneuropathy, in addition to hyperglycemia, are age and the duration of diabetes (Lasker 1993; 46). A genetic predisposition may also be important.

There is an increased body of evidence that vascular risk factors, including elevated triglyceride level, body-mass index, smoking, and hypertension, are independent risk factors for developing diabetic neuropathy (55; 46; 137).

Impaired glucose tolerance is a confirmed risk factor for developing diabetes mellitus. Patients with slightly elevated fasting glucose and HbA1c will develop frank diabetes in the next 5 years with moderate sensitivity (55%) but high specificity (98%), with specificity increasing to 99.6% at 15 years (126). This risk may be lessened with improved outcome from modest weight loss and exercise (130). It is reasonable to assume, and preliminary studies suggest, that such interventions could stabilize or improve the neuropathy. Diet and exercise counseling for impaired glucose tolerance results in cutaneous reinnervation and improved pain as confirmed by intraepidermal nerve fiber density on skin biopsy over 1 year (130).

One study looked at risk factors associated with diabetic neuropathy in Mexican patients and found an association with duration of diabetes as noted previously in other populations, glycemic exposure index, high and low density lipoprotein levels, metformin treatment, smoking, and presence of retinopathy (123).

Epidemiology

The epidemiology of diabetic neuropathies has been studied widely, but the resulting data are conflicting. The two major reasons for this are: (1) the variable criteria used for diagnosing neuropathy, and (2) the failure to recognize the different types of diabetic neuropathies (Table 1). Diagnostic criteria have included neuropathic symptoms, clinical signs of neuropathy, and electrophysiological and other quantitative laboratory abnormalities. Many studies have either concentrated on the entity of diabetic polyneuropathy or have lumped together all forms of diabetic neuropathies. It is estimated that as many as 7.7 million people in the United States have some degree of diabetic peripheral neuropathy. One third of all community-based diabetic patients in the United Kingdom have painful neuropathy symptoms, regardless of their neuropathic deficit (01). Thus, the reported prevalence of symptoms or signs of neuropathy in diabetics has varied from 10% to 100% (45).

The most accurate and informative study to date is the Rochester Diabetic Neuropathy Study (44). In this community-based study, patients were evaluated using neuropathy symptoms and physical signs and disability scores, nerve conduction studies, quantitative sensory testing, and heart rate variation studies. About 60.8% of the subjects had some form of diabetic neuropathy, although the prevalence of symptomatic neuropathy was only 14%. Of the different types of neuropathy, the most frequent by far was sensorimotor polyneuropathy (47.6%). The proportions of subjects with this were similar in the type 1 and in the type 2 groups, although the latter group had more severe manifestations of neuropathy.

Diabetic neuropathy prevalence is lower in newly diagnosed patients, between 3.6% and 19.5%, as shown in large population studies and increases with the duration of diabetes (08; 123). The Danish ADDITION study found a 13% diabetic peripheral neuropathy prevalence in newly diagnosed type 2 diabetes, with a cumulative incidence of 10% over 13 years of age (08). The occurrence of neuropathy is strongly correlated with the duration of diabetes, poor glycemic control, and the presence of retinopathy and nephropathy (123).

In addition, patients presenting with a chronic “idiopathic” axonal polyneuropathy have nearly a twofold higher frequency of undiagnosed diabetes mellitus and impaired fasting blood glucose than age-matched controls. This suggests that an axonal neuropathy may be the presenting or the earliest manifestation in diabetes (69).

Differential diagnosis

Confusing conditions

The mere association of neuropathic symptoms with diabetes mellitus is insufficient for the diagnosis of diabetic neuropathy; therefore, the importance of excluding other causes that might be treated differently or have a different prognosis cannot be overemphasized.

Sensorimotor polyneuropathy. The differential diagnosis is broad and includes several types of hereditary neuropathy as well as numerous causes of acquired neuropathy, including vitamin B12 deficiency, and monoclonal gammopathy of unknown significance. In practice, it is usually safe to assume that in a diabetic with a distal symmetric sensory greater than motor neuropathy, the cause is the diabetes itself. When progression of the neuropathy or proximal weakness is rapid (particularly in the upper limbs), an important consideration is chronic inflammatory demyelinating polyneuropathy.

Autonomic neuropathy. Primary and familial amyloid neuropathy can present with a combination of painful distal sensory neuropathy and autonomic failure. However, in a longstanding diabetic with these features, the overwhelming likelihood is that diabetes is the cause. Amyloid neuropathy, genetic and acquired, should be considered.

Cranial neuropathies. Although pupil-sparing third nerve palsy is a typical complication of diabetes, pupil involvement can occur in a diabetic, as well as posterior communicating aneurysm, tumors, and other mass lesions.

Truncal neuropathy. Acute or subacute onset of trunk pain and cutaneous hypersensitivity should raise the consideration of Herpes zoster, but in that condition the characteristic skin lesions should appear soon after the other symptoms. When the zone of sensory abnormalities is small, an infiltrative lesion of thoracic nerve roots should be considered and imaging studies of the spine performed.

Proximal diabetic neuropathy. Important differential diagnoses include lumbar radiculopathies from a variety of causes, including lumbar canal stenosis, carcinomatous meningitis, and malignant invasion or other mass lesion (hematoma or abscess) of the lumbar plexus.

Associated or underlying disorders

Chronic inflammatory demyelinating polyneuropathy (CIDP). There is controversy as to whether chronic inflammatory demyelinating polyneuropathy occurs more frequently in diabetics than in nondiabetics (134; 73; 62; 37; 127; 83). Although one study suggested a reduced risk of CIDP with diabetes (83), another study indicated a two-fold increased relative risk of diabetes compared with the general population (116). The diagnosis of chronic inflammatory demyelinating polyneuropathy in diabetic patients remains difficult, and it should be clinically based on the typical CIDP phenotype first and foremost and then with electrodiagnostic support (143).

Focal limb mononeuropathies. In most diabetics with focal neuropathies involving the major nerves in the limbs, the underlying causes are similar to those of nondiabetics.

Diagnostic workup

• Sensory and motor nerve conduction studies
• Quantitative sudomotor axon reflex Testing (QSART)
• Cardiac response to deep breathing (R-R interval)
• Cardiac response to Valsalva maneuver
• Tilt table testing
• Thermoregulatory sweat testing
• Quantitative sensory testing
• Skin punch biopsy
• Corneal confocal microscopy

Diagnostic evaluation for suspected diabetes and impaired glucose tolerance. In the case of a patient not known to be diabetic but presenting with a neuropathy, fasting blood sugar and glycosylated hemoglobin levels are often sufficient to make the diagnosis of diabetic neuropathy. If these are negative, an oral glucose tolerance test should be done to evaluate for impaired glucose tolerance (110). Evaluating for features of the metabolic syndrome should also be considered. Intraepidermal nerve fiber density assessed by skin punch biopsy (109) or by skin blister (103) is an emerging technique that is gaining popularity in the diagnosis of small fiber neuropathy and should be included as an endpoint in neuropathy trials. A high index of suspicion is required to diagnose diabetic autonomic neuropathy, and a validated self-reported clinical questionnaire (the Survey of Autonomic Symptoms) improves diagnostic sensitivity (163).

Diagnostic evaluation of diabetic neuropathies. Standard motor and sensory nerve conduction studies and needle electromyographic examination of muscles are the basic techniques used for evaluating the various types of diabetic neuropathies (107). Because nerve conduction studies and needle electromyography evaluate the large diameter myelinated fibers only, they can be misleadingly normal in patients with polyneuropathy in whom the involvement is mainly of the small diameter nerve fibers (small fiber neuropathy). Techniques for evaluating that population of peripheral nerve fibers are discussed below.

Sensorimotor, small fiber, and autonomic polyneuropathy. Several diagnostic modalities are available to study nerves in diabetic neuropathy (Table 2).

Table 2. Diagnostic Modalities Available to Study Nerves in Diabetic Neuropathy

Examination name	Advantages	Disadvantages
Quantitative sensory testing (CASE IV)	Easy to perform, noninvasive, but subjective Evaluates large and small nerve fibers	Variable, subjective, time consuming, not readily available, and requires special equipment
Sudomotor function (QSART and thermoregulatory sweat testing)	Fast, objective, easy to perform, simple, reproducible	Moderate sensitivity, often influenced by drugs, costly, and requires specialized equipment
Sensory and motor NCS	Objective, widely available, gold standard to assess large fibers	Only assesses large fibers, fairly reproducible
Skin punch biopsy (IENFD)	Objective, minimally invasive	Requires special equipment and personnel to quantify
Corneal confocal microscopy	Objective, rapid, reproducible, assesses small fibers	Requires special equipment

CASE IV = computer-assisted sensory examination
QSART = quantitative sudomotor axon reflex test
NCS = nerve conduction studies
IENFD = intraepidermal nerve fiber density

Electrodiagnosis. The electrodiagnostic features of diabetic sensorimotor peripheral polyneuropathy are characteristic of a primarily axon loss sensorimotor polyneuropathy with some evidence of demyelination, which can be quite prominent but insufficient in isolation to make a diagnosis of CIDP. The lower limbs are affected first, so the priority should be for nerve conduction studies to be done there. Because it is usually a symmetrical process, one limb can be studied. The tibial and the peroneal motor nerve conduction studies are performed, recalling that the peroneal motor response recording extensor digitorum brevis is prone to focal muscle damage. The sural nerve and the superficial peroneal sensory nerve actions potentials are essential in evaluating large fiber sensory fibers. Tibial H-reflexes and F waves are useful adjunctive studies. To evaluate if the neuropathy is severe enough to involve the upper limbs, median, ulnar, or radial nerves can be studied. The radial sensory nerve conduction study is preferred because of the propensity for the other nerves to suffer focal nerve entrapment at the elbow or wrist.

Early changes are typically restricted to the lower extremities and consist of one or more of these NCS abnormalities: absent H-reflexes, low amplitude or absent sural and superficial peroneal sensory responses, low amplitude tibial and peroneal motor responses, mild slowing of sensory and motor distal latencies and conduction velocities, and active denervation or reinnervation in distal leg muscles. With more advanced disease, the upper extremities become involved. This often manifests by reduction of the median, ulnar, and radial sensory amplitudes and low or borderline median and ulnar motor amplitudes with mild sensory and motor conduction slowing. In severe diabetic polyneuropathy, there is often complete absence of all routine sensory and motor conduction studies in the legs and absent sensory responses in the hands with very low amplitude median and ulnar motor responses in the upper limbs. The needle electromyography often shows long-duration, high-amplitude, and rapidly recruited motor unit action potentials with or without fibrillation potentials. This is usually symmetrical and worse in the leg muscles distally with a clear distal to proximal gradient.

Neuromuscular ultrasound. Imaging of peripheral nerve using high resolution ultrasonography is increasingly used in clinical practice. Peripheral nerves are enlarged diffusely in diabetics, including those with diabetic polyneuropathy, when compared to controls (21). However, as with other axonal polyneuropathies, the enlargement or nerve morphology changes in patients with diabetic polyneuropathy are often mild with considerable overlap in nerve size between patients and control subjects (135). However, one study showed that high-frequency ultrasound provides valuable findings for diagnosis and monitoring of diabetic neuropathy (75).

The utility of ultrasound in diabetic patients is twofold. First, it is useful in the diagnosis of nerve entrapment syndromes by confirming focal nerve focal cross-sectional area (CSA) enlargement at the entrapment sites, which has been the most commonly reported indicator of nerve pathology. Second, neuromuscular ultrasound may be able to distinguish the axonal nature of diabetic polyneuropathy from the acquired and inherited demyelinating polyneuropathies such as CIDP or Charcot-Marie-Tooth disease (61; 135).

Quantitative sensory testing. Techniques for detecting small nerve fiber involvement include quantitative sensory testing (133; 138). In quantitative sensory testing, graded degrees of warm, cool, or vibration sensations can be applied to the patient's extremities; the thresholds for sensory perception are established and compared with normal values. Temperature sensation is mediated via small diameter nerve fibers, so quantitative sensory testing is a useful complimentary test to nerve conduction studies. Vibration is mediated through large diameter sensory fibers, so testing this modality overlaps with sensory nerve conduction studies. The use of quantitative sensory testing in diabetic neuropathy is specifically reviewed by Chong and Cros (35). Abnormal thresholds for cool and warm sensations may be detected when the nerve conduction studies are normal, confirming the presence of a small fiber or a predominantly small fiber neuropathy. Questions have been raised as to the reproducibility (test-retest reliability) of thermal threshold tests that might limit their use in following the course of neuropathy as in a drug trial study (142). This does not, however, detract from its use as a diagnostic tool in the patient with neuropathic symptoms and normal nerve conduction studies. It takes an hour for one patient and, therefore, less used presently other than for research purposes.

Autonomic testing. Specialized sudomotor evaluation techniques include heart rate variability, quantitative sudomotor axon reflex testing, thermoregulatory sweat testing, and sweat droplet testing (33). Noninvasive cardiovascular procedures, such as heart rate variability with deep breathing or Valsalva maneuver, are relatively sensitive methods for detecting early cardiovagal denervation. A resting tachycardia and a fixed heart rate on deep breathing and going from lying to standing can be demonstrated by EKG recordings. Noninvasive recording of beat-beat blood pressure can be done in specialized laboratories (93; 33). Sudomotor function tests, including thermoregulatory sweat testing and quantitative sudomotor axon reflex test (QSART), may reveal abnormalities. Hemodynamic tilt tests often are valuable when orthostatic hypotension is present.

Several autonomic tests have been recommended (Level B) by the American Academy of Neurology for evaluation of patients with distal symmetric polyneuropathy, including patients with diabetic neuropathy (52). These include:

	• Cardiac response to deep breathing and R-R interval to evaluate cardiovagal functions.
	• Cardiac response to Valsalva maneuvers to test parasympathetic innervation to the heart.
	• Tilt table testing to test adrenergic vasomotor function and cardiac sympathetic function.
	• Quantitative Sudomotor Axon Reflex Testing (QSART) to evaluate the postganglionic segment of the thermoregulatory pathway.
	• Thermoregulatory sweat test, which provides a widespread "geographic" screen of the sudomotor loss.

Gastrointestinal autonomic dysfunction and atony is assessed with various radiographic techniques, but the easiest is simply to demonstrate the abnormally slow passage of barium through the gut (96). To accurately define the nature of neurogenic urinary bladder and sphincter dysfunction, a battery of specialized tests is required. Urinary bladder dysfunction can be investigated by quantitating the post-voiding residual urine, which typically is increased in diabetic cystopathy; cystoscopy and urodynamic studies are required to document and quantitate the degree of bladder dysfunction. Male sexual dysfunction, including erectile impotence, can be differentiated from psychogenic impotence with various tests, including penial tumescence studies during REM sleep.

The nerve fibers that mediate sweating undergo distal damage in polyneuropathies. One electrophysiological technique for evaluating these nerve fibers is to test for sympathetic skin responses. This can be done with most standard EMG machines (101). The utility of this technique for the diagnosis of diabetic neuropathy and diabetic autonomic neuropathy has been questioned (24).

Skin biopsy. This is a technique of distal leg skin punch biopsy with quantification of the epidermal nerve fiber density (68; 65; 78). This is particularly useful in confirming small fiber neuropathy, diabetic or otherwise (84). Intraepidermal nerve fiber density assessing skin blister is likely equivalent to skin punch biopsy (103). Small fiber neuropathy is closely linked to the metabolic syndrome, which consists of diabetes/prediabetes, hypertension, dyslipidemia, and central obesity (159).

Nerve biopsy. This is rarely indicated in patients with sensorimotor or other diabetic neuropathies. It may be of value in the unusual circumstance when the differential diagnoses of amyloidosis or vasculitis are being considered.

Corneal confocal microscopy. Reduced corneal sensation has long been known to occur in patients with diabetic polyneuropathy. The cornea, one of the most densely innervated tissues of the human body, showed reduced sensation symmetrically early in diabetes and this correlates with disease duration (39). Corneal nerve fiber and nerve branch density significantly correlates with intraepidermal nerve fiber density and QST in patients with small fiber neuropathy (74).

Focal limb neuropathies. When encountered in diabetics, carpal tunnel syndrome, ulnar neuropathies at the elbow, and other focal neuropathies are often superimposed on a diabetic sensorimotor polyneuropathy. Nerve conduction studies and needle electromyographic examination can be used to evaluate the presence and severity of such focal neuropathies. Useful strategies to distinguish such focal neuropathies from diabetic polyneuropathy include using internal comparison studies in the hand such as the median-ulnar palmar mixed studies, median-ulnar sensory studies recording ring finger, median-radial sensory studies recording thumb, and median-ulnar comparative motor studies recording second lumbrical-interossei (140). Among these studies, the median-ulnar comparative motor studies recording 2nd lumbrical-interossei is the most useful in patients with suspected carpal tunnel syndrome and superimposed on moderate or severe diabetic polyneuropathy where the sensory studies are either very low or absent (140). More stringent criteria (greater than 0.8 msec vs. greater than 0.5 msec latency difference) are often needed for accurate confirmation of carpal tunnel syndrome in patients with underlying peripheral polyneuropathy.

Diabetic radiculoplexopathy. In patients with this type of neuropathy, nerve conduction studies usually show the presence of distal sensorimotor polyneuropathy. No nerve conduction tests are specifically useful for the diagnosis of diabetic radiculoplexopathy, but reduction of femoral compound action potential amplitude on side-to-side comparison is a helpful clue when present. More helpful is needle electromyographic examination, which usually shows asymmetric neurogenic abnormalities in proximal muscles most often affecting the quadriceps, iliacus, and thigh adductor muscles. These needle electromyographic examination abnormalities may extend as far proximally as the paraspinal muscles. It is important to perform imaging studies of the lumbar spine, the retroperitoneal area, and sometimes the sacrum and pelvis; caution must be used in the diagnosis of compressive radiculopathy in this setting. Cerebrospinal fluid analysis is indicated if there is a suspicion of carcinomatous meningitis producing polyradiculopathy or chronic inflammatory demyelinating polyneuropathy.

Truncal (thoracic) neuropathy. Needle electromyographic examination studies can show neurogenic abnormalities in paraspinal and abdominal muscles at the segmental level of the sensory abnormalities determined clinically. Thermoregulatory sweat testing is useful in confirming the sensory deficit by showing loss of sudomotor function in the involved thoracic spinal nerves. Imaging of the thoracic spine should be considered when the area of sensory symptoms is small, or if there is a lot of pain in the spine itself.

Thermoregulatory sweat testing in male

Thermoregulatory sweat testing in a 58-year-old man who developed dysesthesia and hypersensitivity of skin to touch with modest pain in his abdomen below the rib cage staring slightly asymmetrical on the right and spread quickly t...

Coexisting chronic inflammatory demyelinating polyneuropathy. The diagnosis of CIDP should be clinically based on the typical CIDP phenotype first, after which one can consider whether there is electrodiagnostic supportive evidence (143). Nerve conduction studies and even nerve biopsy unfortunately sometimes fail to distinguish diabetic symmetrical polyneuropathy from chronic inflammatory demyelinating polyneuropathy (134). Cerebrospinal fluid analysis for elevated protein levels is not helpful in this situation either, as an elevated protein may be found in diabetics without neuropathy (134). Neuromuscular ultrasounds are helpful by showing focal and regional enlargements in proximal nerves of the upper extremities and brachial plexus (135). In addition, the positive response to immunotherapy may provide additional evidence for chronic inflammatory demyelinating polyneuropathy.

Management

	• Glycemic control • Treatment of orthostatic hypotension
		- Nonpharmacologic interventions - Pharmacologic therapy
	• Treatment of neuropathic pain
	• Tricyclics
	• Anticonvulsants • SRNI • SSRIs •Antiarrhythmics • Opioids
	• Topical agents
	• Nonpharmacological

Supportive measures are discussed in Peripheral neuropathies: supportive measures and rehabilitation.

Sensorimotor polyneuropathy. The Stockholm Diabetes Intervention Study, the Diabetes Control and Complications Trial, and other studies have shown that tight glucose control can slow the progression of polyneuropathy in type 1 diabetics (09; 117; 72). This tight control extends its protective effect for at least 10 years (04). The UK Prospective Diabetes Study addressed the same question for type 2 diabetics but using different and perhaps less rigorous measures of polyneuropathy (10). The results suggest some benefit after long term intensive glucose control. Pancreas transplantation generally causes the polyneuropathy and diabetic autonomic neuropathy to stop worsening; the former may improve slightly (100). Studies suggest that supervised exercise results in improvements in neuropathic symptoms, neuropathic pain, and cutaneous nerve fiber branching in patients with diabetic peripheral neuropathy (79).

Enormous effort has been put into the search for specific treatments, but the results have been disappointing (18). Such treatments include myoinositol, essential fatty acids, vitamins, protein kinase C inhibitors, vasodilators, antiprostaglandins, ACE inhibitors, lipid lowering agents, advanced glycation end product inhibitors, acetyl-L-carnitine gangliosides, neurotrophic factors, and a variety of aldolase reductase inhibitors (22). The most promising of these in animal models of diabetic sensorimotor neuropathy are the aldolase reductase inhibitors, but they have been generally ineffective in humans, and some have important side effects (03; 22; 54). Alpha-lipoic acid, an antioxidant, has shown promise in some clinical trials and continues to be evaluated in other trials (162; 07). Seal oil omega-3 polyunsaturated fatty acids supplementation increased corneal nerve fiber length in patients with distal sensorimotor polyneuropathy and type 1 diabetes mellitus (86).

Two issues deserve emphasis regarding attempts at treating diabetic sensorimotor neuropathy. The damage may be too advanced by the time the treatment attempts are started, so early intervention is important. It would also seem important to consider multifactorial interventions, including behavior modification (more exercise, better diet, and smoking cessation) and pharmacological therapy, targeting not only hyperglycemia but hypertension, dyslipidemia, and microalbuminuria. Such an approach has been shown to slow progression of retinopathy, nephropathy, and autonomic neuropathy. Disappointingly, there was no impact on sensorimotor neuropathy (56).

Hyperglycemic neuropathy, treatment-related neuropathy, and acute painful sensory neuropathy eventually resolve following the establishment of euglycemia.

Diabetic autonomic neuropathy. There is evidence from both the Diabetes Control and Complication Trial and the UK Prospective Diabetes Study that long-term intensive glucose control improves measures of autonomic function in both types of diabetics (10; 11). It appears that intensive glucose control does not reduce the risk of developing erectile dysfunction (10).

The main requirement in patients with autonomic neuropathy is symptomatic treatment that focuses on the involved organs or systems. Orthostatic hypotension is managed by removing aggravating medications, when possible, instituting nonpharmacological maneuvers such as the head-up tilt of the bed and elastic stockings (102). Effective medical therapy includes fludrocortisone, midodrine, pyridostigmine, and off-label use of droxidopa based on case reports (154; 102; 77). Gastroparesis is treated with dietary manipulation and prokinetic and antiemetic medications; diarrhea and constipation are treated with the medications used in nondiabetics with these symptoms (96). About 50% of diabetic men with erectile dysfunction will respond to sildenafil, tadalafil, or vardenafil. If these fail, intraurethral or intrapenile vasoactive agents, a vacuum constriction device, and penile prostheses are other options (155). Bladder dysfunction requires urologic investigations to define the nature of the dysfunction, which then acts as a guide to management regarding the choice of medications, catheterization, or surgery (155).

Painful third nerve palsy requires analgesics and patching the eye to eliminate diplopia. The management of truncal neuropathy is mainly that of controlling neuropathic pain. Carpal tunnel syndrome should be treated in the same way as in nondiabetics (36). The management of other focal neuropathies in diabetics, such as ulnar neuropathies at the elbow, is less clear.

An open-label uncontrolled study on the treatment of proximal nondiabetic neuropathy with intravenous methylprednisolone had initially produced promising results (47). Multicenter controlled studies are needed to evaluate the efficacy of this medication and that of intravenous immunoglobulin in diabetic radiculoplexopathy (48). A Cochrane review (31) reviewed the only controlled trial in diabetic lumbosacral radiculoplexus neuropathy, which was unpublished (49). This review concluded that there was no evidence to support a positive or negative effect of any immunotherapy in the treatment of diabetic amyotrophy.

High-dose corticosteroids may alleviate pain in this condition. However, due to lack of evidence supporting pain improvement and risk of worsening diabetes, routine use is not recommended. In case of severe pain, intravenous methylprednisolone 1 g may be considered for 3 to 5 days with close blood sugar monitoring while initiating other pain medications. Options for treating the rare case of confirmed chronic inflammatory demyelinating polyneuropathy in a diabetic based on clinical phenotype first followed by electrodiagnostic support includes various prednisone, intravenous methylprednisolone, intravenous immunoglobulin, or plasma exchange as first-line therapy. Other options include azathioprine, mycophenolate mofetil, cyclosporin (134; 73; 143). One small study compared intravenous immunoglobulin with plasmapheresis and found no difference; there was no additional effect when prednisone was added to either (73). All patients in these three studies improved, usually impressively so. The response onset was anywhere from 2 weeks to 4 months and reached its maximum anywhere from 1 to 12 months. There were no recurrences. Another study reported only modest beneficial effects from intravenous immunoglobulin treatment (37).

Pain management. In many of the diabetic neuropathies, a prominent feature is neuropathic pain. The details of the management of neuropathic pain are discussed in other sections; however, a summary of the medications categorized into various levels based on the presence of randomized studies and the level of evidence available for use in the management of neuropathic pain is presented in this section (106). Table 3 and Table 4 are presented for guidelines (151; 19; 16; 146; 106). An evidence-based guideline from 2011 suggested that pregabalin is effective and should be offered for the relief of pain in diabetic neuropathy (Level A), whereas venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, opioids (morphine sulfate, tramadol, and oxycodone controlled-release), and capsaicin are probably effective and should be considered for treatment of painful diabetic neuropathy (Level B) (23). An update to this practice guideline was published in Neurology in December 2021. According to this guideline, the clinicals should be assessed for mood and sleep disorders (Level B). Patients with diabetic neuropathic pain should be offered tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, or sodium channel blockers to reduce pain (Level B). Consider factors other than efficacy (Level B), its effects on function, and quality of life. Consider medication from different classes when patients do not achieve meaningful improvement or if they experience significant adverse effects with the initial therapeutic class (Level B). The use of opioids for the treatment of painful diabetic neuropathy is not recommended (Level B) (113).

Lidocaine patch or cream may be used as an adjunctive treatment; it blocks sodium channels and reduces the hyperexcitability of nociceptors (153). Isosorbide dinitrate spray, a nitric oxide-dependent vasodilator, showed benefit in reducing burning sensation and neuropathic pain (157). There is increasing evidence showing some benefit of alpha lipoic acid in patients with diabetic neuropathy (160; 98; 104). Aldose reductase inhibitor, epalrestat, has been found to reduce neuropathic symptoms (70).

Topical therapy for painful diabetic neuropathy has mainly centered on the use of lower concentration capsaicin cream. A meta-analysis provides some evidence for its efficacy, although true blinding of the studies on which this analysis was made is questionable due to the hyperalgesia following the application of the cream (158). Some patients find this initial hyperalgesia intolerable, and it requires care in its application so that the cream does not get in the patients' mouths or eyes. It is only recommended for use for up to 8 weeks at a time.

In 2020, the 8% capsaicin patch was approved by the FDA for neuropathic pain associated with diabetic peripheral neuropathy (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022395s019lbl.pdf). Results of the 12-week double-blind placebo-controlled trial showed a 30% change in average pain from baseline to week 12 in patients who were treated with the 8% capsaicin patch compared to 22% with placebo. Application site erythema, pain, and pruritus were seen as side effects without any major side effect (129). One controlled study reported that the local application of isosorbide dinitrate spray is helpful in reducing diabetic neuropathic pain (157). Studies support the use of topical capsaicin, glyceryl trinitrate spray, Citrullus colocynthis, nontraditional therapies (Ginko biloba), and other therapies, such as exercise, cognitive behavioral therapy, and mindfulness (113).

In patients with refractory painful diabetic neuropathy, spinal cord stimulation has been shown to provide pain relief and improved quality of life (108; 115). In July 2021, the FDA approved the spinal cord stimulator for pain associated with diabetic neuropathy in the lower limb.

Table 3. Medications for Painful Neuropathy

ORAL PHARMACOLOGIC THERAPY FOR NEUROPATHIC PAIN
Therapy	Starting dose	Maintenance dose
First line
Duloxetine (Cymbalta)	30 mg a day	Increase by 30 to 60 mg increments up to 120 mg a day
Gabapentin (Neurontin)	300 mg tid	Increase by 300 to 400 mg increments to 2400 to 3600 mg daily divided in three to four doses
Pregabalin (Lyrica)	50 mg tid	Increase to 300 mg/day
Tricyclic antidepressants	10–25 mg at bedtime	Increase by 10 to 25 mg increments to 100 to 150 mg at bedtime
Second line
Carbamazepine	200 mg bid	Increase by 200 mg increments to 200 to 400 mg three to four times a day; follow drug levels on doses greater than 600 mg a day
Lamotrigine (Lamictal)	25 mg once a day or bid	Increase by 25 mg increments weekly to 100 to 200 mg bid
Oxcarbazepine (Trileptal)	150 to 300 mg bid	Increase by 300 mg increments to 600 to 1200 mg two times a day
Topiramate (Topamax)	25 to 50 mg at bedtime	Increase by 50 mg increments weekly to 200 mg bid
Valproate	250 mg bid to tid	Increase by 250 mg increments up to 1500 mg a day
Venlafaxine XR (Effexor)	37.5 to 75 mg once a day	Increase by 75 mg increments to 150 to 225 mg a day
Third line
Bupropion SR (Wellbutrin)	150 mg a day	After 1 week, increase to 150 mg bid
Levetiracetam (Keppra)	250 mg at bedtime	Increase by 250 to 500 mg increments to 1500 mg two times a day
Mexiletine	200 mg once a day	Increase by 200 mg increments to a maximum of 200 mg tid
Phenytoin	200 mg at bedtime	Increase by 100 mg increments to 300 to 400 mg daily divided in one to two doses, following drug levels
Tiagabine hydrochloride (Gabitril)	4 mg a day	Increase to 4 to 12 mg bid
Zonisamide (Zonegran)	100 mg at bedtime	Increase by 100 mg increments to 400 to 600 mg at bedtime
Newer drugs
Lacosamide (Vimpat)	50 mg PO bid	After 1 week, go to 100 mg bid May increase up to 200 mg bid
Minacipran (Savella)	12.5 mg at bedtime x 1 d	12.5 mg bid twice daily then 25 mg bid four times daily then stay on 50 mg bid May increase up to 100 mg bid
TOPICAL PHARMACOLOGIC THERAPY FOR NEUROPATHIC PAIN
Therapy	Starting dose	Maintenance dose
Topical agents: over the counter
Capsaicin 0.075%	Apply to affected region tid to qid	Continue with starting dose
Lidocaine 4% gel or cream	Apply to affected region bid	Continue with starting dose
Menthol 16% / Camphor 3% -+	Apply to affected region tid to qid	Continue with starting dose
Salicylate 10% to 15%	Apply to affected region tid to qid	Continue with starting dose
Diclofenac sodium gel (Voltaren gel 1%)	Apply to affected region tid to qid	Continue with starting dose
Lidocaine 4% patch	Apply to affected intact skin	Continue with starting dose and increase up to three patches worn for 12 hours of 24 hours
Topical agents: by prescription
Capsaicin (Qutenza) 8% patch	Apply to the area by health care worker. Single, 30 minute application, up to four topical systems, every 3 months	Continue starting dose every 3 months
Doxepin 5% (Zolopan)	Apply to affected region bid	Continue with starting dose
Lidocaine patch 5%	Apply over adjacent intact skin	Increase up to three patches worn for 12 of 24-hour period
Topical agents: by prescription – only at compounding pharmacies*
Amitriptyline 2% / Lioresal 2%	Apply to affected region tid to qid	Continue with starting dose
Carbamazepine 5% / Lidocaine 5%	Apply to affected region bid	Increase up to a qid schedule
Ketoprofen 5% / Amitriptyline 2% / Tetracaine 1%	Apply to affected region bid	Increase up to a qid schedule
Ketoprofen 10% / Cyclobenzaprine 1% / Lidocaine 5%	Apply to affected region bid	Increase up to a qid schedule
Ketamine 5% / Amitriptyline 4% / Gabapentin 4%	Apply to affected region bid	Increase up to a tid schedule
* Must be compounded by pharmacy (to locate your local compounding pharmacy, call the International Academy of Compounding Pharmacists, 1-800-927-4227)
Adapted and modified from (106).

Table 4. Guidelines for Medication Use in Treating Peripheral Neuropathic Pain

I. Discuss with the patient the principles of the "trial and error" approach.

II. Discuss the principle of titrating drug dosages.

III. Start with routine mild analgesics such as acetaminophen (depending on the severity of the pain) and work up to stronger medications as required.

IV. Start neuropathic pain medications at a low dose and titrate every few days.

V. Increase the dose if pain relief is inadequate and side effects are absent or tolerable.

VI. If the drug is ineffective at high doses, or if side effects prohibit dosage escalation, stop the drug and choose another.

VII. If the drug has been partially successful, consider adding another class of medication, titrating its dose.

With the increased prevalence of chronic nerve entrapments in patients with diabetes mellitus, several authors have proposed that surgical decompression of distal lower extremity peripheral nerves are possibly beneficial in patients with painful diabetic polyneuropathy, as well as in patients with painful cryptogenic polyneuropathy (141). Common sites of proposed decompressions include the tibial nerve at the ankle (including calcaneal, medial, and lateral plantar nerves in the foot), deep fibular (peroneal) nerve at the ankle, common fibular (peroneal) nerve at the knee, lateral femoral cutaneous nerve at the inguinal ligament, and sural nerve in the posterior calf region. However, the role of decompressive surgery for diabetic symmetric distal neuropathy is unproven because there are no well-designed randomized controlled trials (32). A single center randomized study of 42 diabetic patients showed improved pain in the surgical treated foot compared to the contralateral foot and to baseline based on visual analogue scale (95).

One study looked at 306 patients who underwent decompression surgery and were retrospectively assigned to subgroups focal and generalized (88). They confirmed the efficacy of decompression of multiple lower-extremity peripheral nerves in patients with painful diabetic neuropathy with improvement of pain scores, nerve conduction velocity, and cross sectional area, in both focal and diffuse group; however, better results were found in focal group (89). In a review, Liao and colleagues discussed the signs that may serve as prognostic factors for good surgical outcome. This intervention remains to be controversial in diabetic neuropathy, and we caution patients against it until evidence from multicenter controlled trials definitively demonstrates any benefit.

Outcomes

Overall, presently there are not treatments to arrest the progression; however, proper blood sugar control, weight control, and lipid management may slow the progression of diabetic complications. Multiple treatments are available for management of pain.

References

01: Abbott CA, Malik RA, van Ross ER, Kulkami J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34(10):2220-4. PMID 21852677
02: Afshar A, Tabrizi A, Tajbakhsh M, Navaeifar N. Subjective outcomes of carpal tunnel release in patients with diabetes and patients without diabetes. J Hand Microsurg 2020;12(3):183-8. PMID 33408444
03: Airey M, Bennett C, Nicolucci A, Williams R. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev 2000;(2):CD002182. PMID 10796870
04: Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the epidemiology of diabetes interventions and complications (EDIC) study. Diabetes Care 2010;33:1090-6. PMID 20150297
05: Althaus J. On sclerosis of the spinal cord, including locomotor ataxy, spastic spinal paralysis and other system diseases of the spinal cord: their pathology, symptoms, diagnosis, and treatment. London: Green & Company, 1885.
06: American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 2018;41(Suppl1):S13-27. PMID 29222373
07: Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26(3):770-6. PMID 12610036
08: Andersen ST, Witte DR, Dalsgaard EM, et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark. Diabetes Care 2018;41(5):1068-75. PMID 29487078
09: Anonymous. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86. PMID 8366922
10: Anonymous. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998a;41:416-23. PMID 9562345
11: Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998b;352:837-53. PMID 9742976
12: Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983;46:491-9. PMID 6875582
13: Asbury AK. Proximal diabetic neuropathy. Ann Neurol 1977;2:179-80. PMID 617563
14: Auche M. Des alterations des nerfs périphériques. Arch Med Exp Anat Pathol 1890;2:635.
15: Azad N, Emanuele NV, Abraira C, et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications 1999;13(5-6):307-13. PMID 10765007
16: Boulton AJ. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 2004;47(8):1343-53. PMID 15309286
17: Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27(6):1458-86. PMID 15161806
18: Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956-62. PMID 15793206
19: Brannagan TH. Peripheral neuropathy pain: mechanisms and treatment. J Clin Neuromuscular Disease 2003;5:61-71. PMID 19078723
20: Breiner A, Barnett Tapia C, Lovblom LE, Perkins BA, Katzberg HD, Bril V. Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. Neurol Neuroimmunol Neuroinflamm 2019;6(5):e586. PMID 31454771
21: Breiner A, Qrimli M, Ebadi H, et al. Peripheral nerve high-resolution ultrasound in diabetes. Muscle Nerve 2017;55(2):171-8. PMID 27312883
22: Bril V. Status of current clinical trials in diabetic polyneuropathy. Can J Neurol Sci 2001;28:191-8. PMID 11513337
23: Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76(20):1758-65. PMID 21482920
24: Bril V, Nyunt M, Ngo M. Limits of the sympathetic skin response in patients with diabetic polyneuropathy. Muscle Nerve 2000;23:1427-30. PMID 10951447
25: Bruns L. Uber neuritische Lahmungen beim Diabetes Mellitus. Berl Klin Wochenschr 1890;27:509.
26: Callaghan BC, Kerber K, Smith AL, Fendrick AM, Feldman EL. The evaluation of distal symmetric polyneuropathy: a physician survey of clinical practice. Arch Neurol 2012;69(3):339-45.** PMID 22083798
27: Calle-Pascual AL, Duran A, Benedi A, et al. A preventative foot care programme for people with diabetes with different stages of neuropathy. Diabetes Res Clin Pract 2002;57(2):111-7. PMID 12062856
28: Cameron N, Eaton SE, Cotter M, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetalogia 2001;44(11):1973-88. PMID 11719828
29: Capodici A, Hagert E, Darrach H, Curtin C. An overview of common peroneal nerve dysfunction and systematic assessment of its relation to falls. Int Orthop 2022;46(12):2757-63. PMID 36169699
30: Caravati CM. Insulin neuritis: a case report. Va Med Mon 1933;59:745-6.
31: Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev 2017;7(7):CD006521. PMID 28746752
32: Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy. Cochrane Database Syst Rev 2008;(3):CD006152. PMID 18646138
33: Chelimsky TC, Chemali KR. Testing of autonomic function. In: Katirji B, Kaminski HJ, Ruff RL, editors. Neuromuscular disorders in clinical practice. Second edition. New York: Springer, 2014:201-22.
34: Chokroverty S, Reyes MG, Rubino FA, Tonaki H. The syndrome of diabetic amyotrophy. Ann Neurol 1977;2:181-94. PMID 215072
35: Chong PS, Cros DP. Technology literature review: quantitative sensory testing. Muscle Nerve 2004;29(5):734-47. PMID 15116380
36: Clayburgh RH, Beckenbaugh RD, Dobyns JH. Carpal tunnel release in patients with diffuse peripheral neuropathy. J Hand Surg 1987;12A:380-3. PMID 3035004
37: Cocito D, Ciaramitaro P, Isoardo G. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol 2002;249:719-22. PMID 12111305
38: Coppack SW, Watkins PJ. The natural history of diabetic femoral neuropathy. Q J Med 1991;79:307-13. PMID 1852856
39: Cruzat A, Qazi Y, Hamrah P. In vivo confocal microscopy of corneal nerves in health and disease. Ocul Surf 2017;15(1):15-47. PMID 27771327
40: Donaghy M. Diabetic proximal neuropathy: therapy and prognosis. Q J Med 1991;79:287-8. PMID 1852854
41: Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009;94(6):2157-63. PMID 19276232
42: Duchen LW, Anjorin A, Watkins PJ, Mackay JD. Pathology of autonomic neuropathy in diabetes mellitus. Ann Int Med 1980;92:301-3. PMID 6243893
43: Dyck PJ, Davies JL, Wilson DM, Service FJ, O'Brien PC. Risk factors for severity of diabetic polyneuropathy. Diabetes Care 1999b;22:1479-86. PMID 10480512
44: Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24. PMID 8469345
45: Dyck PJ, Melton LJ III, O'Brien PC, Service FJ. Approaches to improve epidemiological studies of diabetic neuropathy: insights from the Rochester Diabetic Neuropathy Study. Diabetes 1997;46(Suppl 2):S5-8. PMID 9285491
46: Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999a;53:2113-21. PMID 10599791
47: Dyck PJ, Norell JE, Dyck PJ. Methylprednisolone may improve lumbosacral radiculoplexus neuropathy. Can J Neurol Sci 2001;28:224-7. PMID 11513340
48: Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002;25(4):477-91. PMID 11932965
49: Dyck PJB, O'Brien P, Bosch EP, et al. The multi-centre double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. Neurology 2006;66(5, Suppl 2):A191.
50: Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008;120(1):1-34. PMID 18616962
51: Eid SA, Rumora AE, Beirowski B, Bennett DL, Hur J, Savelieff MG, Feldman EL. New perspectives in diabetic neuropathy. Neuron 2023;111(17):2623-41. PMID 37263266
52: England JD, Gronseth GS, Franklin G, et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009;72(2):177-84. PMID 19056667
53: Fang F, Wang J, Wang YF, Peng YD. Microangiopathy in diabetic polyneuropathy revisited. Eur Rev Med Pharmacol Sci 2018;22(19):6456-62. PMID 30338814
54: Feldman EL, Sullivan KA, Stevens MJ. Polyolpathway: aldose reductase inhibitors - hope for the future. In: Gries FA, Cameron NE, Low PA, Ziegler D, editors. Textbook of Diabetic Neuropathy. Stuttgart: Thieme, 2003:112-5.
55: Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy. Diabetes Care 1997;46:665-70. PMID 9075809
56: Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno 2 randomised study. Lancet 1999;353(9153):617-22. PMID 10030326
57: Garces-Sanchez M, Laughlin RS, Dyck PJ, Engelstad JK, Norell JE, Dyck JB. Painless diabetic motor neuropathy: a variant of DLRPN? Ann Neurol 2011;69(6):1043-54. PMID 21425185
58: Ge S, Xie J, Zheng L, et al. Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy. Diabetes Res Clin Pract 2016;115:68-75. PMID 27242125
59: Gibbons CH. Treatment induced neuropathy of diabetes. Auton Neurosci 2020;226:102668. PMID 32247944
60: Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010;67(4):534-41. PMID 20437589
61: Goedee HS, van der Pol WL, van Asseldonk JH, et al. Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology 2017;88(2):143-51. PMID 27927940
62: Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000;23:37-43. PMID 10590404
63: Greco D, Gambina F, Pisciotta M, Abrignani M, Maggio F. Clinical characteristics and associated comorbidities in diabetic patients with cranial nerve palsies. J Endocrinol Invest 2012;35(2):146-9. PMID 21399393
64: Gries FA, Cameron NE, Low PA, Ziegler D, editors. Textbook of diabetic neuropathy. Stuttgart, Germany: Thieme, 2003.
65: Griffin JW, McArthur JC, Polydefkis M. Assessment of cutaneous innervation by skin biopsies. Curr Opin Neurol 2001;14(5):655-9. PMID 11562579
66: Gunduz A, Candan F, Asan F, et al. Ulnar neuropathy at elbow in patients with type 2 diabetes mellitus. J Clin Neurophysiol Off Publ Am Electroencephalogr Soc 2020;37(3):220-4. PMID 31425363
67: Hewston P, Deshpande N. Falls and balance impairments in older adults with type 2 diabetes: thinking beyond diabetic peripheral neuropathy. Can J Diabetes 2016;40(1):6-9. PMID 26778679
68: Herrmann DN, Griffin JW, Hauer P, Cornblath DR, McArthur JC. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 1999;53(8):1634-40. PMID 10563605
69: Hoffman-Snyder C, Smith BE, Ross MA, Hernandez J, Bosch EP. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol 2006;63(8):1075-9. PMID 16769858
70: Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006;29:1538-44. PMID 16801576
71: Hur J, Sullivan KA, Callaghan BC, Pop-Busui R, Feidman EL. Identification of factors associated with sural nerve regeneration and degeneration in diabetic neuropathy. Diabetes Care 2013;36(12):4043-9. PMID 24101696
72: Hyllienmark L, Golster H, Samuelssoh U, Ludvigsson J. Nerve conduction defects are retarded by tight metabolic control in type 1 diabetes. Muscle Nerve 2001;24:240-6. PMID 11180207
73: Jaradeh SS, Prieto TE, Lobeck LJ. Progressive polyradiculoneuropathy in diabetes: correlation of variables and clinical outcome after immunotherapy. J Neurol Neurosurg Psychiatry 1999;67:607-12. PMID 10519866
74: Jiang MS, Yuan Y, Gu ZX, Zhuang SL. Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis. Br J Ophthalmol 2016;100(1):9-14. PMID 25677672
75: Jiang W, Liao L, Lai Z, Li K, Luo W, Shen H. Ultrasound evaluation and grading of neuromuscular disease in lower extremities among diabetic patients. Am J Transl Res 2024;16(7):3280-8. PMID 39114677
76: Kazamel M, Stino AM, Smith AG. Metabolic syndrome and peripheral neuropathy. Muscle Nerve 2021;63(3):285-93. PMID 33098165
77: Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83(4):328-35. PMID 24944260
78: Kennedy W, Wendelschafer-Crabb G. Unmyelinated nerves: skin biopsy and skin blister methods. In: Gries FA, Cameron NE, Low PA, Ziegler D, editors. Textbook of Diabetic Neuropathy. Stuttgart, Germany: Thieme, 2003:194-8.
79: Kluding PM, Pasnoor M, Singh R, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabet Complications 2012;26(5):424-9. PMID 22717465
80: Kobessho H, Oishi K, Hamaguchi H, Kanda F. Elevation of cerebrospinal fluid protein in patients with diabetes mellitus is associated with duration of diabetes. Eur Neurol 2008;60(3):132-6. PMID 18628631
81: Kraus WM. Involvement of the peripheral neurons in diabetes mellitus. Arch Neurol Psychiatry 1922;7:202.
82: Lasker RD. The diabetes control and complications trial. Implications for policy and practice. N Engl J Med1993;329(14):1035-6. PMID 8366905
83: Laughlin RS, Dyck PJ, Melton LJ 3rd, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009;73(1):39-45. PMID 19564582
84: Lauria G, Bakkers M, Schmitz C, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 2010;15(3):202-7. PMID 21040142
85: Lee CC, Perkins BA, Kayaniyil S, et al. Peripheral neuropathy and nerve dysfunction in individuals at high risk for type 2 diabetes: the PROMISE cohort. Diabetes Care 2015;38(5):793-800. PMID 25665810
86: Lewis EJH, Perkins BA, Lovblom LE, Bazinet RP, Wolever TMS, Bril V. Effect of omega-3 supplementation on neuropathy in type 1 diabetes: a 12-month pilot trial. Neurology 2017;88(24):2294–301. PMID 28515269
87: Leyden E. Entzundung der peripheren Nerven. Deut Militar Zeitsch 1887;17:49.
88: Liao C, Zhang W. Nerve decompression for diabetic peripheral neuropathy with nerve entrapment: a narrative review. Ther Adv Neurol Disord 2024;17:17562864241265287. PMID 39411723
89: Liao C, Zhang W, Yang M, Ma Q, Li G, Zhong W. Surgical decompression of painful diabetic peripheral neuropathy: the role of pain distribution. PLoS One 2014;9(10):e109827. PMID 25290338
90: Lieb DC, Parson HK, Mamikunian G, Vinik AI. Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp Diabetes Res 2012;2012:878760. PMID 22110481
91: Llewelyn JG, Thomas PK, Fonseca V, King RH, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol 1986;72(2):157-63. PMID 3825515
92: Llewelyn JG, Thomas PK, King RH. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol 1998;245:159-65. PMID 9553846
93: Low PA. Testing the autonomic nervous system. Semin Neurol 2003;23:407-421. PMID 15088262
94: Low PA, Benrud-Larsen LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004;27(12):2942-7. PMID 15562211
95: Macaré van Maurik JF, van Hal M, van Eijk RP, Kon M, Peters EJ. Value of surgical decompression of compressed nerves in the lower extremity in patients with painful diabetic neuropathy. A randomized controlled trial. Plast Reconstr Surg 2014;134(2):325-32. PMID 24732651
96: Malcolm A, Camilleri M. Treatment of diabetic gastroparesis and diarrhea. In: Dyck PJ, Thomas PK, editors. Diabetic neuropathy. 2nd ed. Philadelphia: WB Saunders, 1999:517-29.
97: Massie R, Mauermann ML, Staff NP, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain 2012;135(Pt 10):3074-88. PMID 23065793
98: Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol 2012;2012:456279. PMID 22331979
99: Miller JD, Carter E, Shih J, et al. How to do a 3-minute diabetic foot exam. J Fam Pract 2014;63(11):646-56. PMID 25362495
100: Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997;42:727-36. PMID 9392572
101: Niakan E, Harati Y. Sympathetic skin response in diabetic peripheral neuropathy. Muscle Nerve 1988;11:261-4. PMID 3352661
102: Oldenburg O, Kribben A, Baumgart D, Philipp T, Erbel R, Cohen MV. Treatment of orthostatic hypotension. current opinion in pharmacology 2002;2:740-7. PMID 12482740
103: Panoutsopoulou IG, Wendelschafer-Crabb G, Hodges JS, Kennedy WR. Skin blister and skin biopsy to quantify epidermal nerves: a comparative study. Neurology 2009;72(14):1205-10. PMID 19092108
104: Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014;15(18):2721-31. PMID 25381809
105: Parisi TJ, Mandrekar J, Dyck PJ, Klein CJ. Meralgia paresthetica: relation to obesity, advanced age, and diabetes mellitus. Neurology 2011;77(16):1538-42. PMID 21975198
106: Pasnoor M, Dimachkie MM, Kluding P, Barohn RJ. Diabetic neuropathy part 1: overview and symmetric phenotypes. Neurol Clin 2013;31(2):425-45. PMID 23642717
107: Perkins BA, Bril V. Diabetic neuropathy: a review emphasizing diagnostic methods. Clin Neurophysiol 2003;114(7):1167-75. PMID 12842711
108: Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol 2021;78(6):687-98. PMID 33818600
109: Pittenger GL, Ray M, Burcus NI, et al. Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. Diabetes Care 2004;27(8):1974-9. PMID 15277426
110: Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. JAMA 2003;290(10):1371-6. PMID 12966130
111: Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136-54. PMID 27999003
112: Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 2004;44(12):2368-74. PMID 15607400
113: Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology 2022;98(1):31-43. PMID 34965987
114: Pryce TD. On diabetic neuritis with a clinical and pathological description of three cases of diabetic pseudo-tabes. Brain 1893;16:416.
115: Raghu ALB, Parker T, Aziz TZ, et al. Invasive electrical neuromodulation for the treatment of painful diabetic neuropathy: systematic review and meta-analysis. Neuromodulation 2021;24(1):13-21. PMID 32588933
116: Rajabally YA, Peric S, Cobeljic M, et al. Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicenter comparative reappraisal. J Neurol Neurosurg Psychiatry 2020;91(10):1100-4. PMID 32868389
117: Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9. PMID 8147960
118: Rosoklija GB, Dwork AJ, Younger DS, Karlikaya G, Latov N, Hays AP. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol 2000;99(1):55-62. PMID 10651028
119: Rota E, Zavaroni D, Parietti L, et al. Ulnar entrapment neuropathy in patients with type 2 diabetes mellitus: an electrodiagnostic study. Diabetes Res Clin Pract 2014;104(1):73-8. PMID 24565211
120: Rydberg M, Zimmerman M, Gottsäter A, Nilsson PM, Melander O, Dahlin LB. Diabetes mellitus as a risk factor for compression neuropathy: a longitudinal cohort study from southern Sweden. BMJ Open Diabetes Res Care 2020;8(1):e001298. PMID 32299900
121: Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994;35:559-69. PMID 8179302
122: Sampson MJ, Wilson S, Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med 1990;75(278):635-46. PMID 2217668
123: Sanchez-Pozos K, Monroy-Escutia J, Jaimes-Santoyo J, Granados-Silvestre MLÁ, Menjivar M, Ortiz-López MG. Risk factors associated with diabetic neuropathy in Mexican patients. Cir Cir 2021;89(2):189-99. PMID 33784285
124: Sanjari E, Raeisi Shahraki H, G Khachatryan L, Mohammadian-Hafshejani A. Investigating the association between diabetes and carpal tunnel syndrome: A systematic review and meta-analysis approach. PloS One 2024;19(4):e0299442. PMID 38626071
125: Schmidt RE. Diabetic autonomic neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D, editors. Textbook of Diabetic Neuropathy. Stuttgart-New York: Thieme, 2003:87-91.
126: Selvin E, Wang D, Matsushita K, Grams ME, Coresh J. Prognostic implications of single-sample confirmatory testing for undiagnosed diabetes. A prospective cohort study. Ann Intern Med 2018;169(3):156-64. PMID 29913486
127: Sharma KR, Cross J, Ayyar DR, Martinez-Arizala A, Bradley WG. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002;59(5):751-7. PMID 12020256
128: Shimizu Y, Kozawa J, Hayakawa T, et al. Asymptomatic pontine lesion and diabetic amyotrophy after rapid improvement of poor glycemic control in a patient with type 1 diabetes. Intern Med 2019;58(23):3433-9. PMID 31391398
129: Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain 2017;18(1):42-53. PMID 27746370
130: Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006:29(6);1294-9. PMID 16732011
131: Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med 2012;29(5):578-85. PMID 22023377
132: Stewart JD. Diabetic truncal neuropathy: topography of the sensory deficit. Ann Neurol 1989;25:233-8. PMID 2729914
133: Stewart JD, Freeman R. Quantitative sensory testing. In: Brown WF, Bolton CF, Aminoff MJ, editors. Neuromuscular Function and Disease. Philadelphia: W.B.Saunders, 2002:131-43.
134: Stewart JD, McKelvey R, Durcan L, Carpenter S, Karpati G. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci 1996;142:59-64. PMID 8902721
135: Telleman JA, Grimm A, Goedee S, Visser LH, Zaidman CM. Nerve ultrasound in polyneuropathies. Muscle Nerve 2018;57(5):716-28. PMID 29205398
136: Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285-93. PMID 20876709
137: Tesfaye S, Chaturvedi N, Eaton SEM, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352(4):341-50. PMID 15673800
138: Thaisetthawatkul P. Quantitative sensory testing. In: Katirji B, Kaminski HJ, Ruff RL, editors. Neuromuscular disorders in clinical practice. Second edition. New York: Springer, 2014:223-33.
139: Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997;46(Suppl 2):S54-7. PMID 9285500
140: Ubogu EE, Benatar M. Electrodiagnostic criteria for carpal tunnel syndrome in axonal polyneuropathy. Muscle Nerve 2006;33(6):747-52. PMID 16502422
141: Valdivia Valdivia JM, Weinand M, Maloney CT Jr, Blount AL, Dellon AL. Surgical treatment of superimposed, lower extremity, peripheral nerve entrapments with diabetic and idiopathic neuropathy. Ann Plast Surg 2013;70(6):675-9. PMID 23673565
142: Valk GD, Grootenhuis PA, vanEijk TThM, Bouter LM, Bertelsmann FW. Methods for assessing diabetic polyneuropathy: validity and reproducibility of the measurement of sensory symptom severity and nerve function tests. Diab Res Clin Pract 2000;47:87-95. PMID 10670907
143: Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. J Peripher Nerv Syst 2021;26(3):242-68. PMID 34085743
144: Vazquez Do Campo R, Dyck PJB. Focal inflammatory neuropathies. Handb Clin Neurol 2024;201:273-90. PMID 38697745
145: Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009;14(4):257-67. PMID 20021567
146: Vinik A. CLINICAL REVIEW: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005;90(8):4936-45. PMID 15899953
147: Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(5):1553-81. PMID 12716821
148: Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004;88(4):947-99. PMID 15308387
149: Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115(3):387-97. PMID 17242296
150: Wannarong T, Katirji B. Painless diabetic lumbosacral radiculoplexus neuropathy: a manifestation of treatment-induced neuropathy of diabetes. J Clin Neuromuscul Dis 2020;22(2):121-2. PMID 33214405
151: Watson CP, Watt-Watson JH. Treatment of neuropathic pain: focus on antidepressants, opioids and gabapentin. Pain Res Manage 1999;4:168-78.
152: Weston PJ, Gill GV. Is undetected autonomic dysfunction responsible for sudden death in Type 1 diabetes mellitus. The ‘dead in bed’ syndrome revisited. Diabet Med 1999;16(8):626-31. PMID 10477206
153: Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly 2010;140(21-22):297-306. PMID 20458651
154: Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51:120-4. PMID 9674789
155: Yang CC, Bradley WG. Treatment of diabetic sexual dysfunction and cystopathy. In: Dyck PJ, Thomas PK, editors. Diabetic neuropathy. 2nd ed. Philadelphia: WB Saunders, 1999:530-40.
156: Yee T. Recurrent idiopathic lumbosacral plexopathy. Muscle Nerve 2000;23(9):1439-42. PMID 10951450
157: Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled crossover study. Diabetes Care 2002;25(10):1699-703. PMID 12351464
158: Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin: a meta-analysis. Eur J Clin Pharmacol 1994:45; 517-522. PMID 7995318
159: Zhou L, Li J, Ontaneda D, Sperling J. Metabolic syndrome in small fiber sensory neuropathy. J Clin Neuromuscul Dis 2011;12(4):235-43. PMID 22361523
160: Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with a -lipoic acid over 4 years in diabetic polyneuropathy: the Nathan 1 trial. Diabetes Care 2011;34(9):2054-60. PMID 21775755
161: Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 2014;63(7):2454-63. PMID 24574045
162: Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999;107(7):421-30. PMID 10595592
163: Zilliox L, Peltier AC, Wren PA, et al. Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. Neurology 2011;76(12):1099-105. PMID 21422460
164: Zochodne DW. Diabetes and the plasticity of sensory neurons. Neurosci Lett 2015;596:60-5. PMID 25445357
165: Zochodne DW, Murray MM, van der Sloot P, Riopelle RJ. Distal tibial mononeuropathy in diabetic and nondiabetic rats reared on wire cages: an experimental entrapment neuropathy. Brain Res 1995;698:130-6. PMID 8581471

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Mamatha Pasnoor MD FAAN

Dr. Pasnoor of the University of Kansas Medical Center received honorariums and consulting fees from Argenx BVBA, Immunovant, Janssen, and Sanofi as speaker and medical advisor and honorariums from Grifols as faculty of an ambassador teaching program.
See Profile
Mazen M Dimachkie MD

Dr. Dimachkie, Director of the Neuromuscular Disease Division and Executive Vice Chairman for Research Programs, Department of Neurology, The University of Kansas Medical Center received consultant honorariums from Abcuro, Advanced Clinica Cabaletta Bio, Amicus, Annexon Inc., ArgenX, Astellas, Cabaletta Bio, Catalyst, Covance/LabCorp/Fortrea, CSL Behring, Dianthus, EMD Serono/Merck, Horizon, Ig Society Inc, Ipsen, Janssen, Octapharma, Sanofi Genzyme, Shire/Takeda, and Treat NMD/TACT. Dr. Dimachikie also received research grants from Astellas, Catalyst, CSL Behring, EMD Serono/Merck, Horizon, Janssen, Nuvig, Octapharma, Sanofi Genzyme, Sarepta Therapeutics, Shire/Takeda, and TMA.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University received a consultant honorarium from Roche and Ovid Therapeutics.
See Profile

Former Authors

Eva Feldman MD PhD
John Wald MD
John D Stewart MD
Songkit Supakornnumporn MD
Bashar Katirji MD

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: male>female, >2:1
Heredity: heredity may be a factor
Population groups selectively affected: diabetics
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Diabetic neuropathy, unspecified, for type 1 diabetes: E10.4

Diabetic neuropathy unspecified, for type 2 diabetes: E11.4

Diabetic mononeuropathy, for type 2 diabetes: E11.41

Diabetic polyneuropathy, for type 2 diabetes: E11.42

Autonomic neuropathy due to diabetes: E13.43
ICD-11: Diabetic polyneuropathy: 8C03.0

Mononeuropathy of other specified nerve: 8C12.Y

Diabetic radiculoplexoneuropathy: 8B94

Diabetic autonomic neuropathy: 8D88.1

Diabetic Charcot arthropathy: FA38.10

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Diabetic neuropathies

Associated Disorders

Bell palsy
Carpal tunnel syndrome
Chronic inflammatory demyelinating polyneuropathy
CIDP
Meralgia paresthetica
- Superimposed chronic inflammatory demyelinating polyneuropathy
- Third nerve palsy
- Ulnar neuropathy

Differential Diagnosis

Primary amyloid neuropathy (Primary systemic amyloidosis: neurologic complications)
Hereditary amyloid polyneuropathy
Posterior communicating aneurysm (Unruptured cerebral aneurysms)
Mass lesions involving cranial nerves
Infiltrative lesion of thoracic nerve roots
- Lumbar radiculopathies
- Carcinomatous meningitis (Leptomeningeal metastasis)
- Nerve plexus metastasis
- Vitamin B12 deficiency
- Alcoholic neuropathy (Alcohol abuse and its neurologic complications)
- Endocrine neuropathies
- Mass lesions involving the third nerve
- Herpes zoster (Varicella-zoster virus infections of the nervous system)

Also Relevant

Acute autonomic neuropathies
Autonomic neuropathy: treatment
Chronic autonomic neuropathies
Clinical evaluation of peripheral neuropathies
Complex regional pain syndrome
- Diabetic amyotrophy
- Duloxetine
- Neuropathic pain: treatment
- Nutrition-related peripheral neuropathies
- Outpatient rehabilitation of chronic neurologic conditions
- Pain
- Peripheral neuropathies: supportive measures and rehabilitation
- Pregabalin
- Principles of rehabilitation of patients with neurologic disorders
- Sexual dysfunction in neurologic disorders
- Small fiber neuropathies
- Vasculitic neuropathies

Clinical Categories

Patient Handouts

Web References

Guidelines

AAN: Surgical decompression for diabetic neuropathy

Testing

Diabetes and Hearing Loss

Clinical Trials

NIH: Diabetic Neuropathies

Diabetic neuropathies

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Table 1. Classification of Diabetic Neuropathies

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Table 2. Diagnostic Modalities Available to Study Nerves in Diabetic Neuropathy

Management

Table 3. Medications for Painful Neuropathy

Table 4. Guidelines for Medication Use in Treating Peripheral Neuropathic Pain

Outcomes

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Mental status examination

Carbon disulfide neuropathy

Toxic peripheral neuropathies

Organophosphate neuropathy

Turcot syndrome

Upadacitinib

Diphtheritic neuropathy

Efgartigimod alfa and hyaluronidase-qvfc

This is an article preview.
Start a Free Account
to access the full version.